Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: CD4 and FOXP3 as predictive markers for the recurrence of T3/T4a stage II colorectal cancer: applying a novel discrete Bayes decision rule

Fig. 2

Survival analysis after surgery based on the optimal maker subsets of TILs. A RFS based on the total number of patients. B RFS based on the absence of adjuvant therapy. C RFS based on the presence of adjuvant therapy. The cut-off values to distinguish high and low cell densities were 339.1, 72.2, 64.6, and 89.1 cells/mm2 for CD3, CD8, CD4, and FOXP3, respectively. W/M, well/moderately differentiated; Other, poorly differentiated/mucinous/undifferentiated; Hist., histologic grade; p-value, log-rank test

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us